Floatz logo

Ari-0001

B-cell Acute Lymphoblastic Leukemia

Kara Yakhteh Tajhiz Azma CompanyCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

48 Active assets in the B-cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Blinatumomab
SWOG Cancer Research Network
Phase 4BB
Chimeric Antigen Receptor Modified T Cells Infusion
Shenzhen Geno-Immune Medical Institute
Phase 2BB
Tisagenlecleucel
Assistance Publique - Hôpitaux de Paris
Phase 3BB
cd19-ucart
Beijing GoBroad Hospital
Phase 2BB
Fludarabine
National Cancer Institute (NCI)
Phase 3B

View all 50 →

Same molecule, other indications

Ari-0001 is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
Acute Lymphoblastic Leukemia ,LymphomasDormant
B
Indicative ·
60 / 100
View asset →
Primary Mediastinal B-cell Lymphoma (PMBCL)Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →